PE: What impact will DTC programs have on generic drug prices? O’Dell: Not much today, but generics are not completely immune ...

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) ...

In today’s Pharmaceutical Executive Daily, we cover the resignation of Organon CEO Kevin Ali following an internal investigation tied to Nexplanon sales, GSK’s $357 million agreement with Syndivia to ...

Shortly following the announcement of its acquisition of Syndivia’s ADC, GSK entered into a worldwide exclusive license ...

The FDA has approved a new single-injection, once-monthly maintenance regimen for Eli Lilly’s Omvoh (mirikizumab-mrkz), ...

The FDA has updated the label for Merck’s Winrevair (sotatercept-csrk) following results from the Phase III ZENITH trial, confirming the therapy’s ability to reduce the risk of clinical worsening ...

Organon announced that CEO Kevin Ali intends to resign from his position following results from an internal investigation ...

In today’s Pharmaceutical Executive Daily, we cover the FDA approval of Bayer’s Lynkuet for menopausal hot flashes, new research suggesting Ozempic may reduce biological age, and Novartis’ $12 billion ...

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

Novartis will acquire Avidity Biosciences in a newly announced definitive merger agreement. The news follows the separation ...

PE: What makes TrumpRx different from other government-run health programs? O’Dell: TrumpRx is different in that its ...

Obesity is a complex, treatable medical condition, not just a matter of willpower, requiring a shift in perception and ...